QIAGEN and NVIDIA partner on AI drug discovery

QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery. The integration helps researchers understand disease biology and uncover biomarkers for developing new medicines. Initial pilot programmes will be available to select pharmaceutical and biotechnology partners. Credit: Gorodenkoff / Shutterstock.com. QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery. The move aims to allow pharmaceutical and biotechnology researchers to use AI more effectively by leveraging enhanced bioinformatics tools and curated knowledge bases. LOA and PTSR Model -…

Salong Debbarma · 2026-05-20

QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.

Source: Pharmaceutical Technology